Mankind Pharma Q4 Consol Net Profit 4.21 Billion Rupees IBES Est. 3.60 Billion Rupees

Published on 21/05/2025 at 18:05

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Mankind Pharma Limited

Jefferies Adjusts Mankind Pharma's Price Target to INR3,000 From INR2,870, Keeps at Buy	11/07	MT
India's Torrent Pharma to acquire controlling stake in JB Chem and Pharma	30/06	RE
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market	27/06	RE
Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market	26/06	RE
Mankind Pharma Incorporates Not-for-Profit Subsidiary	03/06	MT
Maneane Pharma Limited Announces Intimation of Incorporation of A Wholly Owned Subsidiary Company	02/06	CI
Mankind Pharma Limited, Q4 2025 Earnings Call, May 21, 2025	27/05
Jefferies Adjusts Mankind Pharma's Price Target to INR2,870 From INR3,300, Keeps at Buy	23/05	MT
Mankind Pharma to Incorporate Wholly Owned Subsidiary in Sri Lanka	22/05	MT
India's Mankind Pharma beats profit estimates on demand for drugs to treat chronic illnesses	21/05	RE
Mankind Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2025	21/05	CI
Mankind Pharma Q4 Consol Net Profit 4.21 Billion Rupees IBES Est. 3.60 Billion Rupees	21/05	RE
Mankind Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	21/05	CI
Mankind Pharma Says Tax Authority Raises Additional Tax Demand Of 763 Mln Rupees	14/05	RE
Mankind Pharma Says Tax Authority Raised Additional Tax Demand Of 1.28 Billion Rupees	09/05	RE
Mankind Pharma Gets Board Nod to Form Two Subsidiaries	15/04	MT
Mankind Pharma To Incorporate Wholly Owned Subsidiary In Russia	14/04	RE
Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary, Directly or Indirectly, in Russia and Wholly Owned Subsidiary Under Section 8 of the Companies Act, 2013	14/04	CI
Mankind Pharma Limited Announces Issuance of Debt Securities for the Half Year Ended March 31, 2025	11/04	CI
Mankind Pharma Says NCLT Approves Amalgamation Of BSV Pharma With Bharat Serums And Vaccines	28/03	RE
Mankind Pharma Says IT Authority Raises Additional Tax Demand Of 1.83 Billion Rupees	28/03	RE
CARE Withdraws Ratings on Mankind Pharma's Debt Instruments	26/03	MT
Certain Equity Shares of Mankind Pharma Limited are subject to a Lock-Up Agreement Ending on 20-MAR-2025.	20/03	CI
Mankind Pharma Limited Receives Order Issued by Deputy Commissioner State Tax, Trimurti Nagar, Nagpur	01/03	CI
Mankind Pharma Says Income Tax Department Raises Additional Tax Demand Of 1.12 Billion Rupees	28/02	RE